Vir Biotechnology, Inc. VIR Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Vir Biotechnology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Vir Biotechnology, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vir Biotechnology, Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vir Biotechnology, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Vir Biotechnology, Inc. (VIR) reported accretion (amortization) of discounts and premiums, investments of -$394K in Q1 2026.
- How has Vir Biotechnology, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Vir Biotechnology, Inc.'s accretion (amortization) of discounts and premiums, investments increased by 90.4% year-over-year, from -$4.09M to -$394K.
- What is the long-term trend for Vir Biotechnology, Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 2 years (2022 to 2025), Vir Biotechnology, Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a 2.9% compound annual growth rate (CAGR), from $8.94M to -$9.47M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This metric represents the non-cash adjustment to reconcile net income for the amortization of discounts or premiums on investment securities held by the company. It reflects the gradual recognition of interest income or expense over the life of the investment. Investors use this to understand the impact of investment accounting on reported cash flows from operations.